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26 ABSTRACT 
 
27 Background: For any new vaginal dosage form, the distribution and retention in the vagina 
28 has to be assessed by in-vivo evaluation. We evaluated the vaginal distribution and retention of 
29 starch-based pellets in sheep as live animal model by gamma scintigraphy  (using Indium-111 
30 DTPA as radiolabel) and in women via magnetic resonance imaging (MRI, using a gadolinium 
 
31 chelate as contrast agent). A conventional cream formulation was used as reference in both studies. 
 
 
32 Method: Cream and pellets were administered to sheep (n=6) in a two period-two treatment 
33 study and to healthy female volunteers (n=6) via a randomized crossover trial. Pellets (filled into 
34 hard gelatin capsule) and cetomacrogol cream, both labeled with Indium-111 DTPA (for gamma 
35 scintigraphy) or with gadolinium chelate (for MRI) were evaluated for their intravaginal distribution 
36 and retention over a 24 h period. Spreading in the vagina was assessed based on the part of the 
37 vagina  covered  with  formulation (expressed  in  relation  to  the  total  vaginal  length).  Vaginal 
38 retention of the formulation was quantified based on the radioactivity remaining in the vaginal area 
39 (sheep study), or qualitatively evaluated (women study). 
 
 
40 Results: Both trials indicated a rapid distribution of the cream within the vagina as complete 
 
41 coverage of the vaginal mucosa was seen 1 h after dose administration. Clearance of the cream was 
42 rapid: about 10% activity remained in the vaginal area of the sheep 12 h post-administration, while 
43 after 8  h only a thin layer of  cream was detected on the vaginal mucosa  of women. After 
44 disintegration of the hard gelatin capsule, the pellet formulation gradually distributed over the entire 
45 vaginal mucosa. Residence time of the pellets in the vagina was longer compared to the semi-solid 
46 formulation: after 24 h 23 ± 7 % radioactivity was detected in the vaginal area of the sheep, while in 
47 women the pellet formulation was still detected throughout the vagina. 
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48 Conclusion: A multi-particulate system containing starch-based pellets was identified as a 
49 promising novel vaginal drug delivery system, resulting in complete coverage of the vaginal 
50 mucosa and long retention time. 
 
 
51 
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55 1.  INTRODUCTION 
 
56 There is an increasing interest in novel vaginal drug delivery systems with special emphasis 
57 on enhancing the product distribution and retention in the vagina as these are important for locally 
58 acting drugs as well as for those intended for systemic delivery (Alexander et al., 2004; Richardson 
59 and Illum, 1992; Vermani and Garg, 2000). Currently, several conventional vaginal formulations 
 
60 are available on the market, mainly semisolid (creams, gels) and solid (capsules, tablets, ovules, 
61 rings) dosage forms. However all of them are associated with specific disadvantages, contributing 
62 to poor patient compliance: semisolids are messy to administer, cause leakage and have a limited 
63 residence time (Hussain and Ahsan, 2005), while tablets and capsules results in poor disintegration 
64 and require frequent administrations due to self cleansing action of vagina. Although vaginal 
65 retention can be improved by using bioadhesive tablet, loss of these tablets has also been reported 
66 after vaginal application (Voorspoels et al., 2002). Vaginal rings are only suitable for long-term 
67 controlled drug delivery. 
 
 
68 We have  recently proposed,  disintegrating starch-based  pellets  as  a  new vaginal  drug 
69 delivery dosage form.  Evaluation of their distribution and retention in the human vagina by 
70 colposcopy indicated that these disintegrating starch-based pellets distributed evenly over the 
71 vaginal epithelium with a longer retention time compared to non-disintegrating microcrystalline 
72 cellulose pellets (Poelvoorde et al., 2009). However, since colposcopy is an invasive technique, the 
73 speculum (placed in the vagina at frequent intervals during the study) can influence disintegration 
74 of the hard gelatin capsule and distribution of the pellets. To overcome this drawback, non-invasive 
75 techniques must be used to evaluate vaginal distribution and retention of the starch-based pellets. 
 
 
76 Non-invasive  medical  imaging  techniques  such  as  gamma  scintigraphy  and  Magnetic 
 
77 Resonance  Imaging (MRI)  have  proven  valuable  in  assessing  the  in-vivo  retention  of 
78 pharmaceuticals (Mauck et al., 2008). Gamma scintigraphy has been used extensively to track the 
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79 in-vivo distribution of formulations following nasal, oral, rectal or pulmonary administration via 
80 non-invasive imaging with a short-lived gamma-emitting radioisotope (Davis et al., 1992; Meseguer 
81 et al., 1994; Newman and Wilding, 1999). MRI can be used as a complementary tool to gamma 
82 scintigraphy to study the in-vivo drug distribution, as it offers the possibility to acquire three- 
83 dimensional information on drug distribution together with visualization of the anatomical features 
84 in the vicinity of delivery systems. MRI has been used successfully to detect the vaginal anomalies 
 
85 in the female pelvis (Rouariet et al., 2008), and to determine the intravaginal distribution of gels in 
86 human clinical trials (Barnhart et al., 2004c, 2005a; Omar et al., 2008; Pretorius et al., 2002b). 
87 While most of the studies have used MRI, to visualize the vaginal distribution of gels (15-20), 
88 ovules (Barnhart et al., 2004a; Menon et al., 2007) and rings (Barnhart et al., 2005b; Pretorius et al., 
89 2002a), we used MRI to detect small sized multiparticulates and to evaluate their intravaginal 
90 distribution in women. 
 
 
91 In  the  first  part  of  this  study,  the  multiparticulate  pellet  formulation  and  cream  were 
92 administered intravaginally to sheep, and the distribution and retention (up to 24 h post dose) was 
93 monitored via gamma scintigraphy. The trial design was a two period-two treatment study in 6 
94 sheep, administering pellets and cream with a 6 week interval. Indium-111 DTPA was selected as 
95 radiolabel, based on its half life of 2.8 days allowing data acquisitions up to 24 h. The retention and 
 
96 the distribution of the formulations in the vaginal area were determined over a 24 h period. During 
97 the second part of the study, the pellet and cream formulation were administered in a randomized 
98 cross-over trial to 6 healthy women and the intravaginal distribution and retention was assessed 
99 using  MRI  as  monitoring  tool.  The  main  purpose  of  this  study  was  to  assess  the  time  of 
100 disintegration  of  hard  gelatin  capsule (used  to  administer  the  pellets)  and  to  evaluate  the 
101 intravaginal distribution and retention of the pellets and cream. Both formulations were loaded with 
102 gadoterate  meglumine (Dotarem®)  for  visualization  via  MRI.  Comparison  of  the  gamma 
103 scintigraphy (sheep study) and MRI data (women trial) was performed, which allowed to assess if 
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104 sheep can be used as a model to evaluate the distribution and retention of vaginal drug delivery 
105 systems. 
 
106  
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107 2.  MATERIALS AND METHODS 
 
 
108 2.1. Materials 
 
109 2.1.1. Starch pellets 
 
 
110 Starch-based pellets consisted of a high amylose, crystalline and resistant starch grade 
111 (VELOX™ MCS, Henkel, New Jersey, USA) as main excipient (76.4%). Hydroxypropylmethyl 
 
112 cellulose (HPMC) (Methocel® E15 LV EP Pharm, Colorcon, Dartford, UK) (4.4%) was used as 
 
113 binder and sorbitol  (Sorbidex® P  16615, Cerestar, Vilvoorde, Belgium)  (9.2%) was added  as 
 
114 plasticizer. Demineralized water was used as granulation liquid. Indium-111 DTPA (111In) (t1/2=2.8 
 
115 days)  (Covidien, Petten, Netherlands) and gadoterate meglumine  (Dotarem®, Guerbet, Roissy, 
 
116 France) were used as contrast agents for gamma scintigraphy and MRI, respectively. 
 
 
117 2.1.2. Cream 
 
 
118 A placebo, buffered cetomacrogol cream (pH 4.5) was used as reference formulation, based 
119 on the standardized formulation listed in the „Therapeutisch Magistraal Formularium‟  (a validated 
120 formulary of compounded formulations available to Belgian pharmacists): 7.2% cetostearyl alcohol, 
121 1.8% cetomacrogol 1000, 15% white vaseline, 6% liquid paraffin and water. Sodium dihydrogen 
122 phosphate (0.3%)  was  added  as  buffering  agent,  and 0.02%  propylparaben  and 0.08% 
123 methylparaben as preservatives. All ingredients were purchased from Fagron (Waregem, Belgium). 
 
 
124 2.2. Preparation of pellets 
 
125 Starch-based pellets were produced by extrusion-spheronisation according to Dukic et al. 
126 (Dukic et al., 2007). The contrast agents were dissolved in demineralized water (used as granulation 
 
127 liquid). After dry mixing of all excipients for 15 min in a tumbling mixer (Turbula® model T2A, 
 
128 W.A. Bachofen, Basel, Switzerland), the powder mix was granulated with demineralized water 
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129 (containing the contrast agents) using mortar and pestle. The wet mass was extruded in a bench-top 
130 single screw mini extruder (model MSE, Caleva, Dorset, UK) at an extrusion speed of 50 rpm, 
131 equipped with an extrusion screen with 0.5 mm perforations. The extrudates were spheronised at 
132 1000 rpm for 3 min, in a Model 10 spheroniser (Caleva, Dorset, UK). After overnight drying in an 
133 oven at 40°C, the 315-710 µm size fraction was collected by sieving and about 700 mg pellets were 
134 filled into size 00 hard gelatin capsules (Intercaps, Acapharma, Waregem, Belgium). Each capsule 
 
135 contained  about 18.5  MBq  radioactivity  or 3%  w/w  gadoterate  meglumine  at  the  time  of 
136 administration. 
 
 
137 2.4. Preparation of cream 
 
138 The hydrophilic and lipophilic phases of the cream were separately heated to 70°C. After 
139 mixing both phases, the cream was cooled to room temperature while stirring continuously. Cream 
140 pH was adjusted to 4.5. Immediately prior to dosing, the cream was physically mixed with Indium- 
141 111 DTPA (about 18.5 MBq/5g cream) or gadolinium chelate (final concentration: 3% w/w), and 
142 filled into aluminum tubes coated with epoxy layer. 
 
 
143 2.5. Sheep studies 
 
 
144 2.5.1. Progesterone assay 
 
 
145 Sheep experiments were carried out under approval of the Ethical Committee for Animal 
146 Research (Ghent University). Research was adhered to the “Principles of Laboratory Animal Care” 
147 (NIH publication # 85-23, revised in 1985). Six female sheep (Texel breed) of 7-9 months old with 
148 a body weight between 30 and 35 kg were used. The sheep were housed in holding pens at the 
 
149 Faculty of Veterinary Sciences (Ghent University, Belgium) from 2 weeks prior to the study until 
150 the end of the study. The animals were fed a ewe meal and had free access to water. The animals 
151 were not fasted prior to the study and supply of water was also not affected. At the start of the 
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152 study, the stage of oestrous cycle in all sheep was determined by measuring plasma progesterone 
153 concentration. A blood sample (8 ml) was collected in a heparinised tube, by direct venipuncture of 
154 the jugular vein. Plasma was separated from blood by centrifugation at 3000 rpm and stored at - 
155 20°C awaiting analysis. Plasma progesterone was measured by radioimmunoassay, using a DSL- 
 
156 3900   ACTIVE®  Progesterone   Coated-Tube   Radioimmunoassay  kit (Diagnostic  Systems 
 
157 Laboratories, Texas, USA). The progesterone concentration were very low (0.1-3.5 ng/ml) in all 
 
158 sheep, confirming their anoestrous stage. 
 
 
159 2.5.2. Administration of cream and pellets to sheep 
 
 
160 Initially the radiolabeled cream was administered intravaginally to each sheep and after a 
161 washout period of 6 weeks a hard gelatin capsule filled with radiolabelled pellets was inserted. To 
162 facilitate dose administration, the sheep were lightly sedated with an intramuscular injection of 
 
163 xylazine  (Xyl-M®  2%, VMD, Arendonk, Belgium) at a dose of  0.15 mg/kg body weight. An 
 
164 accurately weighed amount of radiolabeled cream (±5g) was applied deep into the vagina, using 
 
165 applicators supplied with the marketed Gynomyk® cream. Gamma scintigraphy was performed 0, 1, 
 
166 2, 4, 6, 8, 12 and  24 h post administration. After a washout period of six weeks, a control 
167 scintigraphy was performed to confirm the absence of radioactivity in the vagina. Afterwards a hard 
168 gelatin capsule filled with radiolabeled pellets was administered with a commercially available 
169 vaginal  applicator (13  cm  length)  (Infemin applicator, Pierre  Fabre  Santé  Benelux, Brussels, 
170 Belgium) and scans were taken at 0, 4, 6, 8, 12 and 24 h after administration. 
 
 
171 2.5.3. Gamma scintigraphy 
 
 
172 The distribution and retention of the cream  and pellet formulation  in the vagina was 
173 evaluated by gamma scintigraphy, using a Toshiba GCA-901 gamma camera. The fleece on the 
174 head and back of each sheep was marked with animal stock marker and these lines were lined-up 
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175 with marks on the table to ensure that each sheep was roughly in the same position for each 
176 scintigraphic image. The sheep were restrained on the table in right lateral recumbency with the 
177 camera positioned underneath the table centered over the vaginal area and the images were obtained 
178 by  registering  activity  for 2  min.  Processing  and  analysis  of  data  was  performed  with  the 
179 Multimodality  software (version 5)  of  Nuclear  diagnostics (Nuclear  Diagnostic,  Stockholm, 
180 Sweden). 
 
 
181 2.5.4. Vaginography 
 
 
182 To outline the vagina of the sheep a vaginography was performed. A Foley balloon catheter 
183 was  vaginally  inserted  and 20  ml  iopromide  (commercially  contrast  fluid,  Ultravist®,  Bayer 
184 Healthcare Pharmaceuticals, Wayne, NJ) was injected into the balloon catheter, followed by an X- 
185 ray scan. 
 
 
186 2.5.5. Analysis of gamma scintigraphy scans 
 
 
187 The vaginal template outlined via the vaginograms was used to facilitate the drawing of the 
188 regions of interest (ROI) for all scintigraphic images. For each scintigraphic scan, three ROIs were 
189 drawn: i) ROI corresponding to the vaginal area, ii) background ROI and iii) ROI corresponding to 
 
190 the area of initial deposition of the cream or pellet formulation. The total radioactivity (counts per 
191 minute per unit area: cpm/cell) in each vaginal ROI was calculated, by correcting for background 
192 activity  and  radioactive  decay.  To  determine  the  vaginal  retention  of  the  formulation,  the 
193 radioactivity  present  in  the  vaginal  ROI  at  zero  time  was  denoted  as  the  total  amount  of 
194 radioactivity deposited in the vagina (100%). For each scan at subsequent times, the actual activity 
195 was expressed as the percentage of the total activity at time 0 (i.e. administered dose). Hence, the 
196 retention of each formulation in the vagina was evaluated by the decrease of activity against time. 
197 Graphs were plotted of the remaining activity at each time point for all sheep and the area under 
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198 curve (AUC) was calculated. The SPSS statistical software package (version 17, Somers, New 
199 York) was used to perform the statistical analysis by paired sample t-test for the AUC, at a 
200 significance level of 0.05. 
 
 
201 To assess the distribution within the vagina, the longitudinal length of vaginogram was 
202 considered as the vaginal length and based on the spread of the formulations in the vaginal ROI the 
 
203 distribution of the radiolabeled formulations was calculated as percentage of the vaginal length. 
 
 
204 2.6. Women trial 
 
205 2.6.1. Study protocol 
 
 
206 Cetomacrogol  cream  and  starch-based  pellets  were  administered  to 6  healthy  female, 
207 nulliparous volunteers  (age  21-28 years, mean body weight  55.5  ±  4.5 kg) in a randomized, 
208 crossover  trial  and  MRI  was  performed  to  monitor  the  distribution  and  retention  of  the 
209 formulations.  The  study  was  approved  by  the  Institutional  Ethical  Review  Board  of  Ghent 
210 University (Belgium). The research followed the tenets of the Declaration of Helsinki. Subjects 
211 were recruited by written informed consent during their first screening visit and assigned a subject 
212 number. Subjects were compensated for their time and effort. Screening examinations included a 
 
213 brief questionnaire on medical and gynecologic history; thereby also asking for presence of any 
214 genital  symptoms (subject-reported),  a  pregnancy  test,  pelvic  and  colposcopy  evaluation, 
215 assessment of vaginal pH, microscopic examination and culture of a vaginal smear and Chlamydia 
216 test on an endocervical sample. Subjects were excluded from the trial if any infections like 
217 candidiasis, bacterial vaginosis or chlamydiosis were present. To be included in the trial, women 
218 had  to  meet  the  following  criteria:  good  health,  normal  results  from  physical  and 
219 genital/gynecological examination, signed informed consent and regular menstrual cycle. Exclusion 
220 criteria were as follows: clinically significant abnormal physical examination and/or laboratory 
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221 findings;  vaginitis  at  the  time  of  screening,  active  dermatologic  abnormality  of  the  vagina 
222 (including atopic dermatitis, lichenification etc.), history of operations and vaginal hysterectomy, 
223 diagnosed  pelvic  floor  dysfunction,  vaginal  breakthrough  menstrual  bleeding,  pregnancy  and 
224 presence of an intrauterine device or a metal prosthesis, claustrophobia, use of local or systemic 
225 antibiotics (including antifungal and antiprotozoal drugs) from 3 weeks prior to start of the study. 
 
 
226 The initial visit of volunteers was a screening visit, followed by two concurrent visits when 
227 either gadolinium-labeled pellets (filled into hard gelatin capsule) or cream was administered. A 2- 
228 week washout period was respected between both the tests. After cream application, scans were 
229 taken at 0, 1, 4, 8, 24 h, whereas for pellets scanning was done at 0, 4, 8, 12 and 24 h following 
230 initial insertion. 
 
 
231 The formulations were administered to the study subjects by a gynecologist, when they were 
232 lying supine on the MRI scanner. The study subjects were remained supine for 6 h to mimic the 
233 dose administration of vaginal formulations during night time. To minimize activity by the subject, 
234 they were transferred in a wheel chair from the scanner to the resting room. After 6 h, the subjects 
235 were allowed to go home but urged to not do any intensive activity (no sports), during 24 h after 
236 formulation administration. Only light physical activity was allowed. Use of intimate hygiene 
237 products (spray, intimate deo, vaginal solutions) was prohibited. Plucking or trimming of pubic hair 
238 during the trial, use of tampons and intercourse during 24 h trial period were also prohibited. 
 
 
239 2.6.2. Magnetic Resonance Imaging (MRI) 
 
 
240 T1-weighted MRI was performed to evaluate the distribution and retention of the cream and 
241 pellets in women, using a dedicated research 3 T magnet (Magnetom Trio, Siemens, Erlangen, 
242 Germany) with Tim upgrade, Siemens Leonardo workstation and Siemens syngo VB 15 software, 
243 using a pelvic phased-array coil (to allow small fields of view and to increase signal-to-noise ratio). 
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244 Transverse and sagittal T1-weighted sequences were taken: gradient-echo (GE) T1 w sequence (256 
245 matrix, TR/TE 168/4.8), turbo spin-echo (TSE) T1 w sequence (512 TR/TE matrix, 400/12) and T2 
246 w images (256 matrix, TR/TE 1310/89). Digitally stored images of MRI were used to measure the 
247 spread of cream and pellets. A single MR radiologist measured the spread of formulations in the 
248 vagina for each T1 weighted data set. Processing and all measurements were performed with the 
249 internal  MR  scanner  software (Siemens  Syngo).  The  maximum  distances  between  the  high- 
 
250 intensity signal of the contrast-enhanced cream or pellet spread in the transverse and in the sagittal 
251 directions were measured. Total linear length of vagina was measured on T2 images. The linear 
252 spread of  each formulation,  represented by the gadolinium-enhanced  area  in  T1 images  was 
253 measured and subsequently, the distribution was calculated as a percentage of the total linear 
254 vaginal length. Graphs were plotted for vaginal spread in function of time for all subjects and the 
255 area under curve  (AUC) for each graph was calculated. Using SPSS, statistical analysis was 
256 performed by paired sample t-test for AUC of cream and pellet curves, at a significance level of 
257 0.05. 
 
 
258  
 
259  
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260 3. RESULTS 
 
 
261 3.1. Sheep studies 
 
262 Figures 1a and b show representative gamma scintigraphy scans at each time point after 
263 cream and pellet administration, respectively. Leakage of the cream and contamination on the vulva 
264 and tail is clearly distinguished after application of the cream in the vagina. There was no leakage or 
 
265 contamination after vaginal administration of the pellets. Cream already leaked during first 1 h after 
266 administration. This observation is not apparent from the scans as the vulva and tail were cleaned 
267 prior to scanning with decontamination solution (Radiacwash, Biodex Medical Systems, New York) 
268 when leakage was visually observed, in order to get a clear image of the vaginal area in the scans. 
 
 
269 The radioactivity remaining in the vaginal area for the cream and pellet formulations in each 
270 sheep is depicted in Figure 2. Within 1 h of cream administration, a sharp drop in activity was 
271 observed confirming the leakage of cream from the vagina. After 6 h 31 ± 15 % of the cream was 
272 retained in the vagina, while after 12 h cream could only be detected in 2 sheep (about 20% activity 
273 remaining), while in the other 4 sheep the entire dose of administered cream was cleared from the 
274 vagina. Between 35 and 100% of the pellets remained in the vaginal area 4 h after administration, 
 
275 with more than 90% of the pellets detected in 3 sheep. The average pellet retention after 24 h was 
276 23 ± 7 %. The average retention profiles (Figure 3a) showed that both formulations were gradually 
277 cleared after vaginal application, but - in contrast with the cream - a significant fraction of the 
278 pellets still remained in the vagina after 24 h. Statistical analysis of the individual retention curves 
279 (based on the AUC values) confirmed the better performance of the pellets with respect to the 
280 retention in the vagina: AUC after pellet application increased by 622 units (95% CI: 246 - 998, 
281 p=0.008, paired sample t-test) compared to the cream. 
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282 Distribution of the cream and pellets in the vagina (assessed via the procentual spread of the 
283 formulation  over  the  entire  vaginal  length)  indicated  that  the  cream  immediately  distributed 
284 throughout the vagina after administration, while the pellets were initially concentrated at the 
285 application site as they were administered via a hard gelatin capsule (Figure  3b). The cream 
286 remained distributed throughout the vagina during the measurement period. Data about the spread 
287 of cream after 12 and 24 h are not shown as the activity remaining in the vagina is too low to obtain 
 
288 meaningful data. The pellets (administered via a hard gelatin capsule) could only distribute in the 
289 vagina after disintegration of the capsule (4-6 h) and release of pellets in the vagina. Afterwards the 
290 pellets spread throughout the vagina, and radioactivity was still detected in the entire vaginal area 
291 after 24 h. 
 
 
292 3.2. Women trial 
 
293 Figures 4 and 5 show the spread of cream and pellets, respectively, on the sagittal T1- 
294 weighted three-dimensional gradient echo magnetic resonance scans. The contrast between the 
295 cream and the pelvic structures in the MRI scans was high due to gadolinium incorporated in the 
296 cream as an MRI marker. Immediately after administration (0 h), the initial bolus of cream was 
297 primarily located in the upper vagina, but over time the spread extended to the lower vagina. After 1 
298 h the cream had already distributed to the lower vagina and at 4 h a large fraction of the cream was 
299 cleared from the vagina, with only a thin layer of cream lining the vagina at the end of the trial (24 
300 h). All volunteers received about 5 g cream, except volunteer 4, where a second administration was 
301 required due to an initial failure of the applicator, resulting in a total administered amount of about 
302 7 g cream. As a result, leakage at the introitus was observed, as gadolinium was detected on the 
303 MRI scan below the introitus. 
 
 
304 The hard gelatin capsule containing the pellets was applied at the anterior fornix in  3 
305 subjects and at the posterior fornix in the other 3, as assessed via MRI scans at 0 h. At 0 h, no high 
 
15  
 
 
 
 
 
306 intensity (white)  signal  of  gadolinium  was  detected  on  the  MRI  scans,  as  the  marker  was 
307 incorporated in the pellets as a dry powder. This created the susceptibility artifact, seen as a black 
308 spot deep in the vagina (Figure 5, scan at 0 h). The MRI signal of the pellets only intensified after 
309 disintegration of the capsule, release of the pellets and dissolution of the gadolinium chelate label. 
310 MRI data indicated that in 5 volunteers the pellets were released from the capsule within 4 h, but 
311 that the spread was limited to upper vagina (cervical area). In one volunteer, disintegration of the 
 
312 capsule occurred between 4 and 8 h after administration. At the 8 h time point, the pellets had 
313 spread to the lower part of the vagina. At 12 and 24 h pellets were detected throughout the vagina. 
314 Both the pellet and cream formulation had spread into the endocervical canal of 2 volunteers. 
 
 
315 Figure 6A shows a sagittal MRI scan, illustrating the parts of the vagina used to measure the 
316 linear spread of cream and pellets within the vagina. The linear spread is a assessment of the part of 
317 the vagina along the axis from the cervix to the introitus covered with the formulation, expressed as 
318 a percentage of the total linear length of the vagina (Barnhart et al., 2004a).   Figures 6 b and c 
319 present the transverse images for cream (at 1 h) and pellets (at 24 h), respectively, visualizing the 
320 W-shape of the vagina confirming the complete coverage of the vaginal mucosa with cream and 
321 pellets. Figure 7 represents the individual vaginal spread profiles over a 24 h period for both cream 
322 and pellets, in all volunteers. 
 
 
323 In volunteer 3, the pellet spread at 12 h could not be clearly detected, however at 24 h 80% 
324 of vaginal area was covered by the pellet formulation. Discontinuous spread of the pellets in some 
325 parts of the vagina was observed, which might be due to an insufficient amount of vaginal fluid, 
326 reducing the wetting of the pellets and decreasing visualization of the formulations in the scans. The 
327 radiologist reported a very mobile uterus in volunteer 6 (e.g. anteflexion, cranioversion), which 
 
328 affected the reproducibility of the spread measurement in the vagina. 
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329 Although the AUC data of the linear spread vs. time profile (Figure 7) did not indicate a 
330 significant difference between cream and pellet (mean difference: 337 unit, 95% CI: -186 to 860, p 
331 = 0.159), the behavior of these formulations during the first hours of the test was different. The 
332 cream immediately covered a large portion of the vagina and the spread remained fairly constant 
333 throughout the entire test period  (although  - as previously mentioned  - the amount of cream 
334 residing  in  the  vaginal  cavity at  the  later  time  points  was  minimal).  In  contrast,  the  pellet 
 
335 formulation gradually spread throughout the vagina as disintegration of the hard gelatin capsule and 
336 wetting and disintegration of the pellets was needed before the material could distribute in the 
337 vaginal cavity. In addition variability of the pellet spread was higher (specifically at the initial time 
338 points) as intravaginal disintegration of the hard gelatin capsule will be variable. 
 
 
339 Quantitative assessment  of the MRI data  (to  determine the percentage of formulation 
340 remaining in the vagina at each time point) was not done as the MRI marker (gadolinium) was 
341 present in a dry form in the pellet formulation and differences in the amount of gadolinium 
342 dissolved at each time point would affect the intensity of the MRI signal, hence preventing accurate 
343 quantification of the MRI scans. 
 
 
344  
 
345  
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346 4. DISCUSSION 
 
347 Intravaginal formulations are used either for treatment of local infections (e.g., vaginitis, 
348 vaginal atrophy), for systemic drug delivery (e.g., delivery of steroids for hormone replacement 
349 therapy) or for preventive measures  (e.g., spermicides for contraception, microbicides for HIV 
350 prevention). Based on the desired effect of treatment, the medication should be retained at a specific 
 
351 area or cover the entire vagina and should remain in contact with the vaginal mucosa for a 
352 significant period of time. Hence, quantification and optimization of the distribution of intravaginal 
353 formulations is essential (Barnhart et al., 2001). 
 
 
354 The interest in using animal models other than nonhuman primates for the evaluation of 
355 vaginal formulation is evident. Sheep are good candidates to fulfill this role based on a number of 
356 criteria. They have a size that facilitates conventional gamma camera imaging as opposed to small 
357 laboratory animals, and their vagina has comparable characteristics to the human vagina. The 
358 vaginal length is 9-13 cm in sheep and 8-12 cm in women. The cervical diameter in women is 2.3- 
359 3.3 cm, versus  1-1.15 cm in sheep. Furthermore, histological evaluation of sheep vagina and 
360 cervical epithelium indicated that the stratified squamous epithelium overlying the dense vascular 
361 submucosa is thinner but similar in structure to human epithelium. Sheep are relatively inexpensive, 
362 easy to handle, and available in large numbers with the ability to control for age, reproductive state 
363 and sexual history (Vincent et al., 2009). Also the vaginal tract in sheep is easily accessible for the 
364 administration of delivery systems and the docile nature of the animal allows the experiments to be 
365 performed without sedation or anesthesia (Richardson et al., 1996). Vincent et al. already used 
366 sheep during toxicity studies to evaluate the epithelial injury in the vaginal tract after exposure to 
367 benzalkonium chloride by colposcopy and tomography. (Vincent et al., 2009). We expanded the use 
 
368 of sheep as model to assess the behaviour of dosage form by evaluating the intravaginal distribution 
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369 and retention of a multiparticulate pellet formulation and a cream, using gamma scintigraphy as 
370 non-invasive imaging technique. 
 
 
371 The use of radiolabeled formulations in combination with gamma scintigraphy is an elegant 
372 and relatively cheap modality to explore their intravaginal distribution and retention. This technique 
373 has  already  been  used  in  sheep  to  monitor  the  retention  and  spreading  of  muco-adhesive 
 
374 microspheres over a 12 h period, after intravaginal administration as a dry powder or dispersed in a 
375 pessary  (Richardson et al.,  1996). Gamma scintigraphic evaluation of vaginal dosage forms in 
376 women indicated limited intra-subject, but considerable inter-subject variability in clearance: after 6 
377 h between 2 and 80 % of the formulations (radiolabeled pessary and polycarbophil gel) was cleared 
378 in post-menopausal women (Brown et al., 1997), while Chatterton et al. determined that the vaginal 
 
379 retention of a clotrimazole cream and test gel (both labeled with 99mTc-DTPA) in pre-menopausal 
 
380 women after 24 h ranged 1 and 81% of the administered dose (Chatterton et al., 2004). Similar to 
381 our trial, these studies did not report migration of the formulations to the surrounding organs 
382 (uterus, urinary bladder). 
 
 
383 The gamma scintigraphic scans indicated that the cream formulation  (having a similar 
384 viscosity as commercially available creams intended for vaginal application) was immediately 
385 available within the entire vaginal cavity. However, the cream continuously leaked from the vagina, 
386 resulting in a fast clearance of the formulation which would require frequent application in a 
387 clinical situation. In contrast, vaginal residence time of the pellets was prolonged as even at the end 
388 of the evaluation period  (24h) a significant amount of tracer was detected in the vaginal area. 
389 However, a drug incorporated in the pellet formulation will not be immediately available as the hard 
390 gelatin capsule (used to administer the pellets intravaginally with the aid of an applicator) needs to 
 
391 disintegrate.  The  in-vivo  disintegration  time  of  hard  gelatin  capsules  after  intravaginal 
392 administration to women was in excess of 4 h (determined via colposcopy)  (Poelvoorde et al., 
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393 2009). The starch-based pellets can only disintegrate in the vaginal fluids after opening of the 
394 capsules, and afterwards the material will distribute throughout the vagina. Once the pellets were 
395 released from the hard gelatin capsule, the formulation distributed over the entire vagina. In contrast 
396 to the cream formulation, the loss of the pellets from the vagina over time was not due to 
397 continuous leaking of material, but linked to urination. 
 
 
398 To assess the value of sheep as model to evaluate the behaviour of dosage forms after 
399 vaginal  application,  both  formulation (starch-based  pellets  and  cetomacrogol  cream)  were 
400 administered to women. To avoid exposure of the volunteers to a radioactive marker, MRI was used 
401 as non-invasive, non-ionizing imaging technique. Gadolinium was used as contrast agent as it was 
402 reported to be an accurate marker to study the intravaginal distribution of a gel since it did not leak 
403 from the formulation during distribution (Barnhart et al., 2001; Barnhart et al., 2006). 
 
 
404 An important quantitative measure to monitor the distribution of dosage forms within the 
405 vagina is the linear spread, i.e. the total linear length along the axis of the vagina where formulation 
406 can be detected  (Barnhart et al., 2001; Barnhart et al., 2005a; Pretorius et al., 2002b). This 
407 parameter indicated the immediate distribution of the cream throughout the vagina, but MRI also 
408 visualized a rapid clearance of the cream (although only qualitatively assessed based on the thin 
409 lining  of  contrast  agent  on  the  vaginal  mucosa 8  and  24  h  after  cream  application.  These 
410 observations are consistent with our scintigraphic data obtained in sheep and with an MRI study 
411 monitoring gel distribution in women (a gradual decrease in mucosal coverage over time, with 
412 minimal coverage at 24 h after application of 3.5 ml gel) (Barnhart et al., 2005a). By contrast, the 
413 pellet formulation gradually distributed throughout the vagina (since disintegration of the capsule 
414 was required before spreading of the formulation could occur). The exact time point of capsule 
 
415 disintegration is not determined, but MRI scans indicated that in 5 women the capsule opened 
416 within  4 h of administration. However, at the initial time point  (4 h) the pellets were mainly 
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417 concentrated in the upper vagina. Based in the qualitative assessment of the MRI scans the 
418 residence time of the pellets was longer compared to the pellets as a high intensity signal was 
419 detected in the upper part of the vagina at the end of the evaluation period. This observation is 
420 consistent with our sheep study. 
 
 
421 The  W-shape  of  the  vagina  identified  in  the  transverse  images (axial  plane)  indicate 
 
422 complete coverage of the vaginal mucosa with formulation, as a thin coating of material separates 
423 the anterior and posterior walls of the vagina (Barnhart et al., 2004b). Using the cream the complete 
424 coverage was already seen at 1 h based on the rapid distribution of the cream, while the W-shape 
425 was most obvious for the pellets at 12 and 24 h. 
 
 
426 Although different techniques were used to monitor the behavior of the formulations in 
427 sheep (gamma scintigraphy) and women (MRI) since no MRI equipment for veterinary application 
428 was available at the study site and exposure of the women to ionizing radiation was avoided, the 
429 similar trends observed for the distribution and retention (albeit based on qualitative analysis for 
430 MRI data) of the cream and pellet formulations during both studies support that sheep are a suitable 
431 animal model for future evaluation of vaginal dosage forms. 
 
 
432 Both the sheep and women study indicated that the starch-based pellets performed better 
433 after intravaginal delivery compared to cream, as their retention time was longer (>24 h), reducing 
434 the application frequency. Compared to the cream (or semi-solids in general) starch-based pellets 
435 also provide a better option for the patient towards patient compliance, as semi-solids are less 
436 convenient (messiness, leakage) (Hussain and Ahsan, 2005) and more prone to dosage errors upon 
437 self administration (Garg et al., 2003). However, to take full advantage of the  therapeutical benefits 
438 of these starch-based pellets for vaginal drug delivery, optimization of the final dosage forms is 
 
439 essential since the main constraint of the evaluated formulation is the long in vivo disintegration 
440 time of the capsule  (±  4 h) after intravaginal administration. However, this problem could be 
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441 overcome, either by using specially designed applicators (prefilled with pellets and sealed with a 
442 membrane)  to  allow  direct  introduction  of  the  pellets  in  the  vagina  or  by  developing  fast 
443 disintegrating tablets containing the starch-based pellets. Research in this area is ongoing. 
 
444  
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445 5. CONCLUSIONS 
 
446 Multiparticulate starch-based pellets have been identified a promising new vaginal drug 
447 delivery system, based on their complete coverage of the vaginal mucosa (similar to cream) and 
448 long retention time (> 24 h) after intravaginal administration to sheep and women. We have also 
449 demonstrated that sheep have the potential to become a good model for evaluating the retention and 
 
450 distribution characteristic of intravaginal formulations. 
 
 
451  
 
452  
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Figure(s)  
 
 
 
 
1 Figure 1. Gamma scintigraphy scans after vaginal administration of (a) cream and (b) starch-based 
2 pellets (filled into hard gelatin capsule). These images show scans of a specific sheep (sheep 1). 
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13 Figure 2. Retention profiles of radiolabeled cream () and pellet () formulations in the vaginal 
14 area after vaginal administration to sheep (n=6). 
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18 Figure 3. Mean retention of activity (a) and mean spread in the vaginal area (b) after vaginal 
19 administration of cream () and pellet () formulation to sheep (n=6). Error bars indicate standard 
20 deviations. 
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25 Figure 4. Sagittal T1-weighted three-dimensional gradient echo magnetic resonance scans obtained 
26 0, 1, 4, 8 and 24 h after intravaginal administration of cream. Circle identifies the vaginal area with 
27 a high contrast between cream and pelvic structures due to the incorporation of gadolinium. At 0 h 
28 cream was primarily located in the upper vagina. At 1 h, distribution had extended to the lower 
29 vagina. At 4 h most of the cream was cleared from the vagina, with only a thin layer remaining at 
30 the end of the trial (24 h). 
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36 Figure 5. Sagittal T1-weighted three-dimensional gradient echo magnetic resonance scans obtained 
37 0, 4, 8, 12 and 24 h after administration of capsule filled with pellets. Circle identifies the vaginal 
38 area with a high contrast between pellets (released from disintegrated capsule) and pelvic structures 
39 due to the incorporation of gadolinium.  At 0 h the capsule was intact and visible as a black spot 
40 deep into the vagina, as gadolinium was not in contact with water. At 4 h pellets were released from 
41 the capsule but the spread was limited to the upper vagina (cervical area). At 8 h, the pellet spread 
 
42 had extended to the lower part of the vagina. After 12 and 24 h, pellets were spread throughout the 
43 vagina. 
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48 Figure 6. A) Sagittal image illustrating the parts of vagina used for measurement of the linear 
49 spread, B) transverse image 1 h after cream administration, C) transverse image 24 h after pellet 
50 administration. The W-shape of the vagina is identified in the transverse images, indicating 
51 complete vaginal coverage with the formulations. 
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56 Figure 7. Vaginal spread profiles over a 24 h period after intravaginal administration of the cream 
57 () and pellet () formulations to 6 volunteers. The vaginal spread is expressed as the percentage 
58 of the total vaginal length covered by the formulation. ). 
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62 Figure 8. Mean (n=6) vaginal spread profile over a 24 h period after intravaginal administration of 
63 the cream () and pellet () formulations. The vaginal spread is expressed as the percentage of the 
64 total vaginal length covered by the formulation. Error bars indicate standard deviations. 
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